Brightening the picture for Illumina Inc. were two pieces of news: the sale of its San Diego facilities for $42 million (with a 10-year lease-back agreement) and the settlement of a court battle with Applera Corp. (BioWorld Today)

After revealing favorable results from three multicenter clinical trials of modafinil in attention deficit hyperactivity disorder in children and adolescents, Cephalon Inc. said it expects to seek regulatory approval earlier than previously stated. (BioWorld Today)